IL272281B2 - Methods and preparations for heterologous reprna vaccines - Google Patents
Methods and preparations for heterologous reprna vaccinesInfo
- Publication number
- IL272281B2 IL272281B2 IL272281A IL27228120A IL272281B2 IL 272281 B2 IL272281 B2 IL 272281B2 IL 272281 A IL272281 A IL 272281A IL 27228120 A IL27228120 A IL 27228120A IL 272281 B2 IL272281 B2 IL 272281B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- reprna
- antigenic
- ivt
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538070P | 2017-07-28 | 2017-07-28 | |
| US201762546259P | 2017-08-16 | 2017-08-16 | |
| PCT/US2018/044075 WO2019023566A1 (en) | 2017-07-28 | 2018-07-27 | METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272281A IL272281A (en) | 2020-03-31 |
| IL272281B IL272281B (en) | 2022-12-01 |
| IL272281B2 true IL272281B2 (en) | 2023-04-01 |
Family
ID=63407511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272281A IL272281B2 (en) | 2017-07-28 | 2018-07-27 | Methods and preparations for heterologous reprna vaccines |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11235051B2 (https=) |
| EP (1) | EP3658179B1 (https=) |
| JP (1) | JP7311489B2 (https=) |
| KR (1) | KR102806640B1 (https=) |
| CN (1) | CN111163799A (https=) |
| AU (1) | AU2018306614B2 (https=) |
| BR (1) | BR112020001052A2 (https=) |
| CA (1) | CA3071011A1 (https=) |
| IL (1) | IL272281B2 (https=) |
| MA (1) | MA49693A (https=) |
| SG (1) | SG11202000019RA (https=) |
| WO (1) | WO2019023566A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021010611A2 (pt) * | 2018-12-14 | 2021-08-24 | Glaxosmithkline Biologicals S.A. | Composições e métodos de vacina de reforço (prime boost) heterólogo |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020146700A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| AU2021236068A1 (en) * | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4196128A4 (en) | 2020-08-14 | 2024-06-12 | Arcturus Therapeutics, Inc. | METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES |
| JP2024509769A (ja) | 2021-02-23 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化ｈｉｖエンベロープタンパク質変異 |
| US20240301385A1 (en) | 2021-03-22 | 2024-09-12 | LifeEDIT Therapeutics, Inc. | Dna modifying enzymes and active fragments and variants thereof and methods of use |
| CN115232824B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的预防狂犬病毒感染的疫苗 |
| US20240400619A1 (en) * | 2021-09-02 | 2024-12-05 | Replicate Bioscience, Inc. | Modified alphaviruses with heterologous nonstructural proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| CN119317430A (zh) * | 2022-04-26 | 2025-01-14 | 斯特兰德生物科技公司 | 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途 |
| CN116064597B (zh) * | 2023-01-17 | 2024-04-26 | 北京大学 | 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046621A2 (en) * | 2003-11-12 | 2005-05-26 | The United States Of America As Represented By The Secretary Of The Navy | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| US20140271714A1 (en) * | 2013-03-15 | 2014-09-18 | Monika Simmons | Induction of an immune response against dengue virus using the prime-boost approach |
| WO2016036971A1 (en) * | 2014-09-03 | 2016-03-10 | Bavarian Nordic A/S | Methods and compositions for enhancing immune responses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| EP1497440B1 (en) | 2002-04-25 | 2008-08-20 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP2146760B1 (en) | 2007-04-30 | 2018-10-10 | Medtronic MiniMed, Inc. | Reservoir filling, bubble management, and infusion medium delivery systems and methods with same |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| CA2768186A1 (en) * | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| MX342608B (es) | 2010-07-06 | 2016-10-06 | Novartis Ag * | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. |
| DK2655604T3 (en) * | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| EA027236B1 (ru) * | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| CA2878344A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
| BE1023877B1 (fr) * | 2015-05-21 | 2017-09-01 | Glaxosmithkline Biologicals Sa | Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus |
-
2018
- 2018-07-27 CN CN201880063070.8A patent/CN111163799A/zh active Pending
- 2018-07-27 AU AU2018306614A patent/AU2018306614B2/en active Active
- 2018-07-27 CA CA3071011A patent/CA3071011A1/en active Pending
- 2018-07-27 US US16/634,205 patent/US11235051B2/en active Active
- 2018-07-27 BR BR112020001052-9A patent/BR112020001052A2/pt unknown
- 2018-07-27 SG SG11202000019RA patent/SG11202000019RA/en unknown
- 2018-07-27 KR KR1020207005743A patent/KR102806640B1/ko active Active
- 2018-07-27 EP EP18762177.6A patent/EP3658179B1/en active Active
- 2018-07-27 IL IL272281A patent/IL272281B2/en unknown
- 2018-07-27 WO PCT/US2018/044075 patent/WO2019023566A1/en not_active Ceased
- 2018-07-27 MA MA049693A patent/MA49693A/fr unknown
- 2018-07-27 JP JP2020504146A patent/JP7311489B2/ja active Active
-
2021
- 2021-12-22 US US17/645,556 patent/US11964007B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046621A2 (en) * | 2003-11-12 | 2005-05-26 | The United States Of America As Represented By The Secretary Of The Navy | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| US20140271714A1 (en) * | 2013-03-15 | 2014-09-18 | Monika Simmons | Induction of an immune response against dengue virus using the prime-boost approach |
| WO2016036971A1 (en) * | 2014-09-03 | 2016-03-10 | Bavarian Nordic A/S | Methods and compositions for enhancing immune responses |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3658179C0 (en) | 2025-09-17 |
| EP3658179A1 (en) | 2020-06-03 |
| CN111163799A (zh) | 2020-05-15 |
| MA49693A (fr) | 2020-06-03 |
| JP7311489B2 (ja) | 2023-07-19 |
| US20220111033A1 (en) | 2022-04-14 |
| AU2018306614A1 (en) | 2020-01-30 |
| US11964007B2 (en) | 2024-04-23 |
| SG11202000019RA (en) | 2020-02-27 |
| KR20200037818A (ko) | 2020-04-09 |
| CA3071011A1 (en) | 2019-01-31 |
| JP2020528911A (ja) | 2020-10-01 |
| US20200230225A1 (en) | 2020-07-23 |
| IL272281A (en) | 2020-03-31 |
| US11235051B2 (en) | 2022-02-01 |
| IL272281B (en) | 2022-12-01 |
| EP3658179B1 (en) | 2025-09-17 |
| KR102806640B1 (ko) | 2025-05-12 |
| AU2018306614B2 (en) | 2024-08-29 |
| BR112020001052A2 (pt) | 2020-09-08 |
| WO2019023566A1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11964007B2 (en) | Methods and compositions for heterologous repRNA immunizations | |
| AU2003297039B2 (en) | Multi-antigenic alphavirus replicon particles and methods | |
| AU2007296489B2 (en) | Alphavirus replicon particles matched to protein antigens as immunological adjuvants | |
| US11229692B2 (en) | Methods and compositions for inducing protective immunity against RSV infection | |
| CN107106673A (zh) | 用于增强免疫应答的方法和组合物 | |
| Chang et al. | Polyplex nanomicelle delivery of self-amplifying RNA vaccine | |
| AU2024208643A1 (en) | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE | |
| HK40031089B (en) | Methods and compositions for heterologous reprna immunizations | |
| HK40031089A (en) | Methods and compositions for heterologous reprna immunizations | |
| EA043316B1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ | |
| EP4612305A1 (en) | Binary self-amplifying nucleic acid platform and uses thereof | |
| EA047117B1 (ru) | Аденовирусные векторы и их применения | |
| WO2018210871A1 (en) | Methods and compositions for inducing protective immunity against rsv infection |